102 related articles for article (PubMed ID: 16461788)
1. CD154 gene therapy for human B-cell malignancies.
Messmer D; Kipps TJ
Ann N Y Acad Sci; 2005 Dec; 1062():51-60. PubMed ID: 16461788
[TBL] [Abstract][Full Text] [Related]
2. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia.
Chu P; Deforce D; Pedersen IM; Kim Y; Kitada S; Reed JC; Kipps TJ
Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3854-9. PubMed ID: 11891278
[TBL] [Abstract][Full Text] [Related]
3. Rapid and efficient nonviral gene delivery of CD154 to primary chronic lymphocytic leukemia cells.
Li LH; Biagi E; Allen C; Shivakumar R; Weiss JM; Feller S; Yvon E; Fratantoni JC; Liu LN
Cancer Gene Ther; 2006 Feb; 13(2):215-24. PubMed ID: 16082377
[TBL] [Abstract][Full Text] [Related]
4. In vivo activation of signal transducer and activator of transcription 1 after CD154 gene therapy for chronic lymphocytic leukemia is associated with clinical and immunologic response.
Battle TE; Wierda WG; Rassenti LZ; Zahrieh D; Neuberg D; Kipps TJ; Frank DA
Clin Cancer Res; 2003 Jun; 9(6):2166-72. PubMed ID: 12796382
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis.
Kater AP; Dicker F; Mangiola M; Welsh K; Houghten R; Ostresh J; Nefzi A; Reed JC; Pinilla C; Kipps TJ
Blood; 2005 Sep; 106(5):1742-8. PubMed ID: 15914559
[TBL] [Abstract][Full Text] [Related]
6. Immunogenetic therapy for B-cell malignancies.
Kipps TJ; Chu P; Wierda WG
Semin Oncol; 2000 Dec; 27(6 Suppl 12):104-9. PubMed ID: 11225994
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154.
Wierda WG; Castro JE; Aguillon R; Sampath D; Jalayer A; McMannis J; Prussak CE; Keating M; Kipps TJ
Leukemia; 2010 Nov; 24(11):1893-900. PubMed ID: 20882050
[TBL] [Abstract][Full Text] [Related]
8. CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack.
Kater AP; Evers LM; Remmerswaal EB; Jaspers A; Oosterwijk MF; van Lier RA; van Oers MH; Eldering E
Br J Haematol; 2004 Nov; 127(4):404-15. PubMed ID: 15521917
[TBL] [Abstract][Full Text] [Related]
9. CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53.
Dicker F; Kater AP; Prada CE; Fukuda T; Castro JE; Sun G; Wang JY; Kipps TJ
Blood; 2006 Nov; 108(10):3450-7. PubMed ID: 16741250
[TBL] [Abstract][Full Text] [Related]
10. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia.
Wierda WG; Cantwell MJ; Woods SJ; Rassenti LZ; Prussak CE; Kipps TJ
Blood; 2000 Nov; 96(9):2917-24. PubMed ID: 11049967
[TBL] [Abstract][Full Text] [Related]
11. A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia.
Loeder S; Zenz T; Schnaiter A; Mertens D; Winkler D; Döhner H; Debatin KM; Stilgenbauer S; Fulda S
Cancer Res; 2009 Dec; 69(23):8977-86. PubMed ID: 19920200
[TBL] [Abstract][Full Text] [Related]
12. Induction of CD95 upregulation does not render chronic lymphocytic leukemia B-cells susceptible to CD95-mediated apoptosis.
Romano C; De Fanis U; Sellitto A; Chiurazzi F; Guastafierro S; Giunta R; Tirelli A; Rotoli B; Lucivero G
Immunol Lett; 2005 Feb; 97(1):131-9. PubMed ID: 15626485
[TBL] [Abstract][Full Text] [Related]
13. Gene transfer of CD40-ligand to dendritic cells stimulates interferon-gamma production to induce growth arrest and apoptosis of tumor cells.
Tomihara K; Kato K; Masuta Y; Nakamura K; Uchida H; Sasaki K; Tanaka T; Huang J; Hiratsuka H; Hamada H
Gene Ther; 2008 Feb; 15(3):203-13. PubMed ID: 17989706
[TBL] [Abstract][Full Text] [Related]
14. Gene transfer of noncleavable cell surface mutants of human CD154 induces the immune response and diminishes systemic inflammatory reactions.
Masuta Y; Kato K; Tomihara K; Nakamura K; Sasaki K; Takahashi S; Hamada H
J Immunother; 2007 Oct; 30(7):694-704. PubMed ID: 17893562
[TBL] [Abstract][Full Text] [Related]
15. Efficient adenovirus-mediated gene transduction of normal and leukemic hematopoietic cells.
Huang MR; Olsson M; Kallin A; Pettersson U; Tötterman TH
Gene Ther; 1997 Oct; 4(10):1093-9. PubMed ID: 9415316
[TBL] [Abstract][Full Text] [Related]
16. Activated autologous T cells exert an anti-B-cell chronic lymphatic leukemia effect in vitro and in vivo.
Di Ianni M; Moretti L; Terenzi A; Bazzucchi F; Del Papa B; Bazzucchi M; Ciurnelli R; Lucchesi A; Sportoletti P; Rosati E; Marconi PF; Falzetti F; Tabilio A
Cytotherapy; 2009; 11(1):86-96. PubMed ID: 19153855
[TBL] [Abstract][Full Text] [Related]
17. Gene therapy and active immune therapy of hematologic malignancies.
Wierda WG; Kipps TJ
Best Pract Res Clin Haematol; 2007 Sep; 20(3):557-68. PubMed ID: 17707840
[TBL] [Abstract][Full Text] [Related]
18. Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells.
Kato K; Chu P; Takahashi S; Hamada H; Kipps TJ
Exp Hematol; 2007 Mar; 35(3):434-42. PubMed ID: 17309824
[TBL] [Abstract][Full Text] [Related]
19. Gene therapy of hematologic malignancies.
Wierda WG; Kipps TJ
Semin Oncol; 2000 Oct; 27(5):502-11. PubMed ID: 11049018
[TBL] [Abstract][Full Text] [Related]
20. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.
Lagneaux L; Gillet N; Stamatopoulos B; Delforge A; Dejeneffe M; Massy M; Meuleman N; Kentos A; Martiat P; Willems L; Bron D
Exp Hematol; 2007 Oct; 35(10):1527-37. PubMed ID: 17697742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
